1.Accili, D. 2004. Lilly lecture 2003: the struggle for mastery in insulin action: from triumvirate to republic. Diabetes 53:1633-42.
2.Bach, J. F. 1994. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15:516-42.
3.Bogardus, C., S. Lillioja, B. V. Howard, G. Reaven, and D. Mott. 1984. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 74:1238-46.
4.Cheatham, B., and C. R. Kahn. 1995. Insulin action and the insulin signaling network. Endocr Rev 16:117-42.
5.Ciaraldi, T. P., S. E. Nikoulina, and R. R. Henry. 2002. Role of glycogen synthase kinase-3 in skeletal muscle insulin resistance in Type 2 diabetes. J Diabetes Complications 16:69-71.
6.Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-9.
7.Dandona, P., A. Aljada, and A. Bandyopadhyay. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7.
8.DeFronzo, R. A. 1988. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-87.
9.DeFronzo, R. A., D. Simonson, and E. Ferrannini. 1982. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23:313-9.
10.Del Prete, G., E. Maggi, P. Parronchi, I. Chretien, A. Tiri, D. Macchia, M. Ricci, J. Banchereau, J. De Vries, and S. Romagnani. 1988. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 140:4193-8.
11.Eldar-Finkelman, H., S. A. Schreyer, M. M. Shinohara, R. C. LeBoeuf, and E. G. Krebs. 1999. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 48:1662-6.
12.Garcia-Zepeda, E. A., C. Combadiere, M. E. Rothenberg, M. N. Sarafi, F. Lavigne, Q. Hamid, P. M. Murphy, and A. D. Luster. 1996. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol 157:5613-26.
13.Goudet, G., S. Delhalle, F. Biemar, J. A. Martial, and B. Peers. 1999. Functional and cooperative interactions between the homeodomain PDX1, Pbx, and Prep1 factors on the somatostatin promoter. J Biol Chem 274:4067-73.
14.Hanson, R. W., and L. Reshef. 1997. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 66:581-611.
15.Herzig, S., F. Long, U. S. Jhala, S. Hedrick, R. Quinn, A. Bauer, D. Rudolph, G. Schutz, C. Yoon, P. Puigserver, B. Spiegelman, and M. Montminy. 2001. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413:179-83.
16.Isakoff, S. J., C. Taha, E. Rose, J. Marcusohn, A. Klip, and E. Y. Skolnik. 1995. The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake. Proc Natl Acad Sci U S A 92:10247-51.
17.Keegan, A. D., K. Nelms, L. M. Wang, J. H. Pierce, and W. E. Paul. 1994. Interleukin 4 receptor: signaling mechanisms. Immunol Today 15:423-32.
18.Kern, P. A., S. Ranganathan, C. Li, L. Wood, and G. Ranganathan. 2001. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-51.
19.Kopelman, P. G. 2000. Obesity as a medical problem. Nature 404:635-43.
20.Lowell, B. B., and G. I. Shulman. 2005. Mitochondrial dysfunction and type 2 diabetes. Science 307:384-7.
21.Lu, M., C. Miller, and J. F. Habener. 1996. Functional regions of the homeodomain protein IDX-1 required for transactivation of the rat somatostatin gene. Endocrinology 137:2959-67.
22.Massillon, D., N. Barzilai, W. Chen, M. Hu, and L. Rossetti. 1996. Glucose regulates in vivo glucose-6-phosphatase gene expression in the liver of diabetic rats. J Biol Chem 271:9871-4.
23.McCutcheon, L. J., R. J. Geor, S. E. Pratt, E. Martineau, and K. Ho. 2006. Effects of prior exercise on components of insulin signalling in equine skeletal muscle. Equine Vet J Suppl:330-4.
24.Mittelman, S. D., Y. Y. Fu, K. Rebrin, G. Steil, and R. N. Bergman. 1997. Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia. J Clin Invest 100:3121-30.
25.Muller, S., S. Martin, W. Koenig, P. Hanifi-Moghaddam, W. Rathmann, B. Haastert, G. Giani, T. Illig, B. Thorand, and H. Kolb. 2002. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45:805-12.
26.Murphy, E., K. Shibuya, N. Hosken, P. Openshaw, V. Maino, K. Davis, K. Murphy, and A. O''Garra. 1996. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med 183:901-13.
27.Nikoulina, S. E., T. P. Ciaraldi, S. Mudaliar, P. Mohideen, L. Carter, and R. R. Henry. 2000. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49:263-71.
28.Nordlie, R. C., J. D. Foster, and A. J. Lange. 1999. Regulation of glucose production by the liver. Annu Rev Nutr 19:379-406.
29.Pearce, N. J., J. R. Arch, J. C. Clapham, M. P. Coghlan, S. L. Corcoran, C. A. Lister, A. Llano, G. B. Moore, G. J. Murphy, S. A. Smith, C. M. Taylor, J. W. Yates, A. D. Morrison, A. J. Harper, L. Roxbee-Cox, A. Abuin, E. Wargent, and J. C. Holder. 2004. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter. Metabolism 53:1322-30.
30.Perriello, G., R. Jorde, N. Nurjhan, M. Stumvoll, G. Dailey, T. Jenssen, D. M. Bier, and J. E. Gerich. 1995. Estimation of glucose-alanine-lactate-glutamine cycles in postabsorptive humans: role of skeletal muscle. Am J Physiol 269:E443-50.
31.Pickup, J. C., and M. A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-8.
32.Pickup, J. C., M. B. Mattock, G. D. Chusney, and D. Burt. 1997. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-92.
33.Pilkis, S. J., and D. K. Granner. 1992. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54:885-909.
34.Plutzky, J., G. Viberti, and S. Haffner. 2002. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 16:401-15.
35.Pradhan, A. D., J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 286:327-34.
36.Rao, R., C. M. Hao, R. Redha, D. H. Wasserman, O. P. McGuinness, and M. D. Breyer. 2007. Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. Diabetologia 50:452-60.
37.Schnyder, B., S. Lugli, N. Feng, H. Etter, R. A. Lutz, B. Ryffel, K. Sugamura, H. Wunderli-Allenspach, and R. Moser. 1996. Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Blood 87:4286-95.
38.Schuster, D. P., and V. Duvuuri. 2002. Diabetes mellitus. Clin Podiatr Med Surg 19:79-107.
39.Shaw, M., P. Cohen, and D. R. Alessi. 1997. Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 416:307-11.
40.Wang, H., P. Maechler, B. Ritz-Laser, K. A. Hagenfeldt, H. Ishihara, J. Philippe, and C. B. Wollheim. 2001. Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. J Biol Chem 276:25279-86.
41.Wellen, K. E., and G. S. Hotamisligil. 2003. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785-8.
42.Wild, S., G. Roglic, A. Green, R. Sicree, and H. King. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-53.
43.Winkler, G., F. Salamon, G. Harmos, D. Salamon, G. Speer, O. Szekeres, P. Hajos, M. Kovacs, K. Simon, and K. Cseh. 1998. Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity. Diabetes Res Clin Pract 42:169-74.
44.Zimmet, P. Z., and K. G. Alberti. 1997. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet 350 Suppl 1:SI1-4.
45.何國鼎. 2004. 介白質素-4與第二型糖尿病之間的關連性. 中山醫學大學免疫學研究所碩士論文.